

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934

JUNE 12, 2000

-----  
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----  
(Address of principal executive offices)

336-229-1127

-----  
(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS

On June 12, 2000, Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-Registered Trademark-) announced that the Company's clinical trials testing division is expanding its established genetic testing capabilities to offer pharmacogenomic services to pharmaceutical and biotechnology companies. Pharmacogenomics involves the use of human DNA sequence variability in the development and prescription of drugs to improve their safety and efficacy. LabCorp incorporates pharmacogenomic testing into clinical trials, where it can be used to correlate patient genotypes to drug responses or clinical endpoints.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL  
INFORMATION AND EXHIBITS

- (c) Exhibit  
20 Press release of the Company dated  
June 12, 2000.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By: /s/BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President,  
General Counsel, Secretary  
and Compliance Officer

Date: June 21, 2000



Laboratory Corporation of America-Registered Trademark- Holdings  
358 South Main Street  
Burlington, NC 27215  
Telephone: 336-584-5171

FOR IMMEDIATE RELEASE

Contact: 336-436-4855  
Pamela Sherry

Shareholder Direct: 800-LAB-0401  
www.labcorp.com

#### LABCORP OFFERS EXPANDED PHARMACOGENOMIC SERVICES

BURLINGTON, N.C., June 12, 2000 - The clinical trials testing division of Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-Registered Trademark-; NYSE: LH) is expanding its established genetic testing capabilities to offer pharmacogenomic services to pharmaceutical and biotechnology companies. Pharmacogenomics involves the use of human DNA sequence variability in the development and prescription of drugs to improve their safety and efficacy. LabCorp incorporates pharmacogenomic testing into clinical trials, where it can be used to correlate patient genotypes to drug responses or clinical endpoints.

LabCorp has applied pharmacogenomic testing in both infectious diseases and oncology. LabCorp was the first clinical trial central laboratory to provide HIV phenotyping and genotyping to determine drug resistance. LabCorp also performed gene amplification and protein overexpression testing for trials of Genentech's breast cancer drug, Herceptin-Registered Trademark-, utilizing patient stratification to improve drug efficacy. In addition, it has assisted drug discovery companies with genetic method development and pre-clinical, single nucleotide polymorphism (SNP) identification and characterization.

"Pharmacogenomics promises a revolution in patient testing that will result in a new paradigm of medical care where therapeutic regimens are safer and more effective," said Scott Neilson, vice president and general manager of LabCorp's clinical trials division. "In the process, it will greatly increase the complexity of testing in clinical trials. This will require central laboratories to be at the leading edge of molecular biology and genetic testing. Given our experience in pharmacogenomic testing for clinical trials, we are uniquely positioned to support clients' drug development efforts."

By collaborating with a number of genomics companies, LabCorp plans to gain broader access to novel genetic markers and technology platforms, which it will in turn apply to developing and validating genetic tests for use in clinical trials.

"By focusing on the assay development expertise of our Center for Molecular Biology and Pathology, we are able to offer pharmacogenomic tests using multiple methodologies and platforms," explained David Johnston, Ph.D., chief scientific officer for LabCorp clinical trials. "This provides our pharmaceutical and biotechnology partners access to the latest technologies in one location. Because we are not limited to single instrument platform or genomics partnership, we can give our clients a variety of approaches that best meet the needs of their studies."

LabCorp employs innovative molecular and biochemical genetics techniques to provide pharmacogenetic testing for CYP450, pharmacogenomic assay development, GLP method validation, SNP genotyping, gene expression analysis, genostratification, and monitoring molecular genetic surrogate markers during clinical trials. Its nationwide network of 2,700 patient service centers facilitates collection of DNA samples for extraction and storage for future pharmacogenomic studies.

Based in Raritan, N.J., LabCorp's clinical trials division is a leading central laboratory supporting global pharmaceutical, biotechnology, and medical device clinical trials with method development and a broad menu of safety and efficacy testing from drug discovery through phase IV.

With headquarters in Burlington, N.C., Laboratory Corporation of America-Registered Trademark- Holdings is a national clinical laboratory organization, which operates facilities for conducting clinical assays and diagnostic testing

throughout the U.S. The company had 1999 revenues of \$1.7 billion and employs approximately 18,000.

The Company noted that each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 1999 and subsequent SEC filings.

For further information, business/financial reporters should contact Pam Sherry, Laboratory Corporation of America-Registered Trademark- Holdings, 358 South Main Street, Burlington, NC 27215, phone: 336-436-4855, e-mail: sherry@labcorp.com. Trade journal reporters should contact Amy Smith, Worldwide Marketing Manager, Clinical Trials, LabCorp, 69 First Avenue, Raritan, NJ 08869; phone: 908-526-2400, e-mail: smitha@labcorp.com.

###